Holen Sie sich die Stockscreener-App
83.36
0.79%
-0.66
Vorhandelsmarkt:
83.54
0.18
+0.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Verona Pharma (VRNA) Opinions on Merck Acquisition News - Quiver Quantitative
Key deals this week: Meta, Boyd Gaming, Merck, Sandstorm Gold, Capgemini and more - Seeking Alpha
Merck & Co., Inc. (MRK)’s CEO Thinks He’s Got $50 Billion Of New Drugs, Says Jim Cramer - Yahoo Finance
Merck to Acquire Verona Pharma in $10B Bid - USA Herald
Top Analyst Reports for Microsoft, Alibaba & Merck - Zacks Investment Research
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Yahoo Finance
With Verona deal, Merck wagers on strength of lung drug’s patents - BioPharma Dive
Merck: Jefferies raises TP after Verona acquisition - MarketScreener
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? - Nasdaq
Merck Animal Health gets FDA nod for Bravecto Quantum (MRK:NYSE) - Seeking Alpha
QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health - Business Wire
Merck & Co. Remains In The BD Game After Verona Takeout - insights.citeline.com
Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration - Insider Monkey
Merck's doravirine/islatravir under FDA review for HIV (MRK:NYSE) - Seeking Alpha
U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire
Merck to acquire UK drugmaker Verona Pharma for $10bn - World Pharmaceutical Frontiers
Merck (MRK) Rises Higher Than Market: Key Facts - Yahoo Finance
Merck & Co.’s Verona Acquisition Marks A Return To Respiratory - insights.citeline.com
In a $10B deal, Merck buys cardio developer Verona - BioWorld MedTech
Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue (NYSE:MRK) - Seeking Alpha
Merck to buy Verona and its lung drug in $10B deal - BioPharma Dive
Merck to Buy Verona Pharma in $10 Billion Deal - The Wall Street Journal
Merck to acquire Verona Pharma for $10 billion - Reuters
Verona Pharma Stock Jumps 20%. It’s Being Bought for $10 Billion by Merck. - Barron's
Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B - Investopedia
Freshfields Guides Merck's $10B Deal For Verona Pharma - Law360
Merck to Buy Verona for $10 Billion as Patent Cliff Looms - Bloomberg.com
Merck Faces Multiple Challenges: Will It Steer Through Successfully? - Nasdaq
Merck Makes Big Respiratory Play With $10B Acquisition of Verona - BioSpace
Transcript : Merck & Co., Inc., Verona Pharma plcM&A Call - MarketScreener
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck - Nasdaq
UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects - Yahoo Finance
Merck: confirms acquisition of Verona Pharma - MarketScreener
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma - MarketWatch
Merck strikes $10bn deal for respiratory drugmaker Verona - Financial Times
Merck to buy Verona Pharma for $10B, adds COPD drug Ohtuvayre | VRNA SEC FilingForm DFAN14A - Stock Titan
Merck to buy lung-disease biotech Verona Pharma for $10 billion | STAT - STAT
BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy - insights.citeline.com
Merck spends $10 billion for Verona, gaining access to its COPD medication - Yahoo Finance
Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda - CNBC
Merck confirms $10B buyout of Verona Pharma (MRK:NYSE) - Seeking Alpha
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade - Business Wire
Merck Nears $10 Billion Deal for Drugmaker Verona, FT Says - Bloomberg.com
Merck: could buy Verona Pharma for $10bn - MarketScreener
Merck & Co.: A Pharma Titan At A Discount (NYSE:MRK) - Seeking Alpha
FDA Grants Priority Review for Merck & Co’s (MRK) WINREVAIR - Yahoo Finance
Merck & Co (MRK) Announces the Approval of ENFLONSIA - Yahoo Finance
Merck & Co. (MRK) Announces that US FDA Approves ENFLONSIA™ For Preventing RSV Lower Respiratory Tract Disease - Yahoo Finance
ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season - Merck.com
Merck & Co. revenue 2006-2024 - Statista
Why the Market Dipped But Merck (MRK) Gained Today - Yahoo
Merck (MRK) Gains as CDC Agenda Omits Gardasil Dose Changes - GuruFocus
Merck stock up as CDC meeting excludes HPV shots (MRK:NYSE) - Seeking Alpha
Merck (MRK) Expands Deals with Chinese Pharma Companies - GuruFocus
Kennedy's new US vaccine panel to discuss measles shot for children - marketscreener.com
Merck Stock Analysis: Is Today’s Massive 2% Spike a Breakout? - Daily Chhattisgarh News
Merck: Phase 3 trial in prostate cancer - MarketScreener
Merck Doses First Patient in Phase 3 Trial of Prostate Cancer Drug Candidate - MarketScreener
Merck (MRK) Begins Phase 3 Trial for New Prostate Cancer Treatment | MRK Stock News - GuruFocus
Breakthrough Prostate Cancer Drug Enters Phase 3 Trial: New Hope for 31% Survival Rate Disease - Stock Titan
2 Dividend Stocks to Buy and Never Sell - The Motley Fool
Dividend Growth Remains a Key Priority for Merck - Insider Monkey
Merck (MRK) Dips More Than Broader Market: What You Should Know - Nasdaq
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC
Supreme Court Decision Lets Fosamax Lawsuit Against Merck (MRK) Proceed - GuruFocus
Merck bid to stop Fosamax suit thwarted by Supreme Court - Seeking Alpha
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy? - Nasdaq
Merck Manuals Launches AI-powered Search Tool, Providing Enhanced Access to Trusted Medical Information and Resources - PR Newswire
Goldman Sachs Remains a Buy on Merck & Co (MRK), Sets a $99.00 PT - Insider Monkey
Merck’s SWOT analysis: stock faces keytruda LOE challenge amid pipeline promise - Investing.com
Merck (MRK) Secures Landmark FDA Approval for Keytruda in Head and Neck Cancer - Daily Chhattisgarh News
Immuno-Oncology and Precision Medicine Trends Led by Merck & Pfizer Boost Gastric Cancer Market Growth - openPR.com
2.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):